APA Alıntı

Price, T., Shen, L., Ma, B., Esser, R., Chen, W., Gibbs, P., . . . Cheng, A. (2019). Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer. Asia Pac J Clin Oncol.

Chicago Stili Alıntı

Price, Timothy, Lin Shen, Brigette Ma, Regina Esser, Wenfeng Chen, Peter Gibbs, Robert Lim, ve Ann‐Lii Cheng. "Phase II APEC Trial: The Impact of Primary Tumor Side On Outcomes of First‐line Cetuximab Plus FOLFOX or FOLFIRI in Patients With RAS Wild‐type Metastatic Colorectal Cancer." Asia Pac J Clin Oncol 2019.

MLA Alıntı

Price, Timothy, et al. "Phase II APEC Trial: The Impact of Primary Tumor Side On Outcomes of First‐line Cetuximab Plus FOLFOX or FOLFIRI in Patients With RAS Wild‐type Metastatic Colorectal Cancer." Asia Pac J Clin Oncol 2019.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..